Overview

IV Iron in Acute Decompensated Heart Failure

Status:
Recruiting

Trial end date:
2022-08-31

Target enrollment:

Participant gender:

Summary

The study aims Compare the effect of addition of IV FERRLECITR (ferric gluconate) to standard therapy to standard therapy alone (without any IV iron treatment) in patients admitted with acute decompensated heart failure.

Phase:

Phase 4

Details

Lead Sponsor:

Rambam Health Care Campus

Treatments:

Ferric Compounds
Ferric gluconate
Iron